Please login to the form below

Not currently logged in
Email:
Password:

Ariana Pharma appoints Mariana Kuras as chief technology officer

She previously worked at Biosystems International and Pfizer

Ariana Pharma has appointed former Pfizer scientist Marian Kuras as the company's chief technology officer.

She will lead technological efforts at the French firm, which provides clinical data analysis services to pharma companies to identify best patient responders, identify patients at risk of adverse events and to remove bias from trials.

Prior to joining Ariana, Dr Kuras spent eight years at French biotech Biosystems International, including four as director of research.

During this period, she was responsible for the development and validation of biomarker platform technologies in several projects across therapy areas that included oncology and neurodegenerative diseases.

Previously, she was a genomics and bioinformatics scientist at Pfizer Global Research and Development in France.

Dr Kuras has serving as an independent scientific expert for the sixth and seventh framework of the European Commission.

"Ariana has become one of the most promising international players in diagnostic and personalised medicine," said Dr Kuras. "By providing a validated solution to the challenge of combining heterogenous data from multiple sources with patient characteristics, Ariana will continue to grow as industry demand continues to increase and I am looking forward to adding my experience to the Ariana effort."

24th August 2012

Share


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore creative

For many years we would receive a brief or enquiry almost always with the same sign off:"...we are not too...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....